Catalent Inc

US

CTLT

Health Care

56.05 ₽

Current price

Strong sell
56.05 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    1312 / 1328

  • Position in country

    14081 / 14179

  • Return on Assets, %

    -12.5

    -2.7

  • Net income margin, %

    -20.2

    2.8

  • EBITDA margin, %

    2.1

    10.8

  • Debt to Equity, %

    135.7

    19.2

  • Intangible assets and goodwill, %

    32.6

    3.6

  • Revenue CAGR 3Y, %

    11.2

    8.5

  • Total Equity change 1Y, %

    -25

    0

  • Revenue Y, % chg

    -13.4

    0.5

  • P/BV

    2.7

    1.5

  • P/S

    2.4

    2.3

  • EV/S

    3.6

    2.4

  • EV/EBITDA

    49.3

    7.4

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    12.7

    51.3

  • Forward P/E

    44.3

    15.6

  • Expected dividend per share

    0

    0

Get an analytical review of this company

Competitors

Ranks

  • Royalty Pharma PLC

    00%

  • Zoetis Inc

    00%

  • Eli Lilly and Co

    00%

  • Bristol-Myers Squibb Co

    00%

  • Organon & Co

    00%

  • Johnson & Johnson

    00%

  • Viatris Inc

    00%

  • Merck & Co Inc

    00%

  • Pfizer Inc

    00%

  • Catalent Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    United States of America

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Pharmaceuticals

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    10175.5

  • Ticker

    CTLT.K

  • ISIN

    US1488061029

  • IPO date

    2014-07-31

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-02-14

  • Date fact. publication of reports

    2023-12-31

Company Description

Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.